The Nuclear Oncology Team at CRCI2NA, Nantes Université, is offering a 12-month postdoctoral position focused on radio-immunobiology and tumor resistance, specifically in the context of targeted alpha therapy. The successful candidate will join a multidisciplinary research environment, collaborating with experts in radiochemistry, radiopharmacy, biology, physics, and clinical nuclear medicine. The research will center on the radio-immunobiological effects of targeted alpha-emitting radiopharmaceuticals, with a strong emphasis on tumor cell resistance mechanisms and immune system interactions. The postdoctoral researcher will contribute to the biological evaluation of innovative vectorized radiopharmaceuticals, primarily through in vitro cellular and molecular approaches.

Main activities include designing and performing in vitro experiments, investigating tumor cell resistance mechanisms, managing cell cultures, performing cell-based functional assays, analyzing experimental data, and contributing to scientific reports and presentations. The position also involves flow cytometry, ELISA, immunoreactivity tests, and strict adherence to health, safety, and radiation protection protocols.

Applicants must hold a PhD in Cancer Biology, Immunology, Nuclear Medicine, Radiopharmaceutical Sciences, or a related field, with 2 to 4 years of relevant research experience. Required skills include advanced cell culture techniques, experience with radiolabeled compounds or targeted radionuclide therapy, knowledge of radiation biology and tumor resistance, and fluency in French and English. The position is funded according to the Inserm postdoctoral salary scale and is based at CRCI2NA, INSERM Unit 1307, Nantes, France. The application deadline is March 31, 2026, with an envisaged start date of April 1, 2026.

For more information, visit the CRCI2NA website or contact Professor Joëlle Gaschet. This opportunity is ideal for candidates interested in radio-immunobiology, tumor resistance, and translational cancer research.